Increased prevalence of erythema multiforme in patients with COVID-19 infection or vaccination.
Increased prevalence of erythema multiforme in patients with COVID-19 infection or vaccination.
复制标题
DOI：
10.1038/s41598-024-52099-z
复制
发表时间：
2024-02-02
影响因子：
4.6
通讯作者：
中科院分区：
文献类型：
--
作者：
几份报告指出，多形性红斑（EM）与COVID-19相关，对患者产生不利影响。然而，由于其中大多数是病例报告，因此难以定量评估其相关性。因此，我们的研究旨在确定在COVID-19背景下EM的患病率。本研究设计为一项基于医院的回顾性横断面研究，研究对象为佛罗里达大学健康医院的注册患者。在数据库中检索了EM、COVID-19感染和COVID-19疫苗的ICD-10代码。计算比值比以评估COVID-19感染或接种疫苗后EM的风险。我们的研究纳入了43，547名有COVID-19感染史的患者，其中92名发生EM。感染COVID-19的患者发生EM的可能性是未感染COVID-19的患者的6.68倍（P < 0.0001）。同样，COVID-19疫苗接种后发生EM的风险为2.7，显著高于一般人群（P < 0.0001）。COVID-19感染或接种疫苗后EM的患病率与一般人群显著不同，突出了在COVID-19感染和/或接种疫苗后监测EM患者的重要性。必须向临床医生和患者宣传COVID-19对EM的影响。
Several reports stated that erythema multiforme (EM) was associated with COVID-19 with detrimental outcomes in patients. However, since most of these are case reports, it is challenging to quantitively assess their associations. Therefore, our study aims to determine the prevalence of EM in the context of COVID-19. The study was designed as a retrospective cross-sectional hospital-based study of registered patients at the University of Florida Health Hospital. The ICD-10 codes for EM, COVID-19 infection, and COVID-19 vaccines were searched in the database. The odds ratio was calculated to assess the risk of EM after COVID-19 infection or vaccination. Our study included 43,547 patients with a history of COVID-19 infection, of whom 92 developed EM. Patients with COVID-19 infection were 6.68 times more likely to have EM than those without COVID-19 (P < 0.0001). Similarly, the risk of developing EM after COVID-19 vaccination was 2.7, significantly higher than the general population (P < 0.0001). The prevalence of EM following COVID-19 infection or vaccination significantly differs from the general population, highlighting the importance of monitoring patients for EM after COVID-19 infection and/or vaccination. It is imperative to disseminate awareness to clinicians and patients regarding the impact of COVID-19 on EM.
登录
查看更多内容
影响因子：
4.8
作者：
Verdecia M;Kokai-Kun JF;Kibbey M;Acharya S;Venema J;Atouf F
通讯作者：
Atouf F
DOI：
10.3390/medicina57080828
发表时间：
2021-08-16
期刊：
Medicina (Kaunas, Lithuania)
影响因子：
--
作者：
Bennardo L;Nisticò SP;Dastoli S;Provenzano E;Napolitano M;Silvestri M;Passante M;Patruno C
通讯作者：
Patruno C
影响因子：
3.8
作者：
Martin Carreras-Presas, Carmen;Amaro Sanchez, Juan;Somacarrera Perez, Maria Luisa
通讯作者：
Somacarrera Perez, Maria Luisa
DOI：
10.1016/j.amsu.2021.103051
发表时间：
2021-12
期刊：
Annals of medicine and surgery (2012)
影响因子：
--
作者：
Saleh W;SHawky E;Halim GA;Ata F
通讯作者：
Ata F
影响因子：
3.2
作者：
Egan, Kevin P.;Wu, Sharon;Wigdahl, Brian;Jennings, Stephen R.
通讯作者：
Jennings, Stephen R.